SCHEMBL3450751

SCHEMBL3450751

CCn1c(C(C)(C)N)nc2ncccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.39
NPY5R Q15761 1/20 0.38
CYP1A2 P05177 2/20 0.38
HTT P42858 2/20 0.38
CYP2D6 P10635 1/20 0.38
RPS6KA5 O75582 1/20 0.36
BACE1 P56817 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 3/20 0.35
ACSS2 Q9NR19 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
CYP2C9 P11712 1/20 0.34
SLC22A12 Q96S37 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14336554 0.87 S1PR1 (0.41) S1PR1NPY5RCYP1A2HTTCYP2D6
SCHEMBL13497667 0.78 HTT (0.60) CYP1A2HTTCYP2D6RPS6KA5ALDH1A1
SCHEMBL25171851 0.77 CYP1A2 (0.59) S1PR1NPY5RCYP1A2HTTCYP2D6
Hydrochloric Acid SCHEMBL31258765 0.76 CYP1A2 (0.57) S1PR1NPY5RCYP1A2HTTCYP2D6
Hydrochloric Acid SCHEMBL25167011 0.76 CYP1A2 (0.57) S1PR1NPY5RCYP1A2HTTCYP2D6
SCHEMBL22090002 0.73 KMT2A (0.42) S1PR1NPY5RCYP1A2HTTCYP2D6
SCHEMBL13497675 0.72 S1PR1 (0.53) S1PR1NPY5RCYP1A2HTTCYP2D6
SCHEMBL10466029 0.71 S1PR1 (0.46) S1PR1NPY5RCYP1A2HTTCYP2D6
SCHEMBL6489159 0.70 HTR3E (0.40) BACE1KMT2ANPC1RAB9AHTR3E
SCHEMBL6489152 0.69 BACE1 (0.39) CYP1A2CYP2D6RPS6KA5BACE1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 US disclosed
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 US disclosed
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 US disclosed
CN-101611018-A Heterocyclic sulfonamide with Edg-I antagonistic activity ASTRAZENECA AB (SE) 2009-12-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY EDF1, ERLIN1, ECE1 S1PR1 800/4885NPY5R 4359/4885CYP1A2 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.